Jean Cui Founder of BlossomHill Therapeutics Backed byVivo CapitalFrank Kung SourcesBlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC — 2025-12 Browse all founders · Browse investors
